Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501).

Francois, Fabien; Naimi, Loubna; Roblin, Xavier; Berger, Anne-Emmanuelle; Paul, Stephane

Francois, Fabien; Naimi, Loubna; Roblin, Xavier; Berger, Anne-Emmanuelle; Paul, Stephane.

Afiliação

Francois F; Department of Immunology, CIC1408, GIMAP U1111/UMR5308 INSERM-UJM-UCBL-ENS de Lyon-CNRS, University Hospital of Saint-Etienne, Saint-Etienne, France.
Naimi L; Department of Immunology, CIC1408, GIMAP U1111/UMR5308 INSERM-UJM-UCBL-ENS de Lyon-CNRS, University Hospital of Saint-Etienne, Saint-Etienne, France.
Roblin X; Department of Gastroenterology, University Hospital of Saint-Etienne, Saint-Etienne, France.
Berger AE; Department of Immunology, CIC1408, GIMAP U1111/UMR5308 INSERM-UJM-UCBL-ENS de Lyon-CNRS, University Hospital of Saint-Etienne, Saint-Etienne, France.
Paul S; Department of Immunology, CIC1408, GIMAP U1111/UMR5308 INSERM-UJM-UCBL-ENS de Lyon-CNRS, University Hospital of Saint-Etienne, Saint-Etienne, France. stephane.paul@chu-st-etienne.fr.

BMC Immunol ; 22(1): 81, 2021 12 25.

Article em En | MEDLINE | ID: mdl-34953484

Assuntos

Medicamentos Biossimilares; Colite Ulcerativa; Adalimumab/farmacologia; Adalimumab/uso terapêutico; Medicamentos Biossimilares/farmacologia; Medicamentos Biossimilares/uso terapêutico; Monitoramento de Medicamentos/métodos; Humanos; Imunoensaio

Palavras-chave

ABP501; AMGEVITA; Adalimumab; Anti-TNFα; Biosimilar; Drug monitoring; HUMIRA

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colite Ulcerativa / Medicamentos Biossimilares Limite: Humans Idioma: En Revista: BMC Immunol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google